Skip to content

Soochow University Neuro-Oncology Cohort Registration Study

Soochow University Neuro-Oncology Cohort Registration Study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600120794
Enrollment
Unknown
Registered
2026-03-19
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurological Tumors

Interventions

Observation group:None

Sponsors

The First Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age 14 years (no upper limit); 2. Pathologically confirmed for the first time as primary or metastatic central nervous system tumor (any category according to WHO 2021) through postoperative tissue or stereotactic biopsy; 3. The date of the initial pathological report is within =500 mg and paired cerebrospinal fluid 5 ml; 7. Having contact information for follow-up (smartphone of the patient or immediate family member/ permanent residence address), and committing to complete at least 24 months of regular follow-up; 8. Signing a written informed consent form.

Exclusion criteria

Exclusion criteria: 1. Non-tumorous space-occupying lesions (demyelinating diseases, vascular malformations, infectious foci, etc.); 2. Pregnancy, lactation, or women of childbearing age with positive serum ß-hCG within 48 hours before enrollment; 3. History or concurrent malignancy, except for the following situations: AJCC stage 0 or stage I solid tumors that have been cured for >=5 years (e.g., cervical carcinoma in situ, thyroid microcarcinoma); 4. Presence of other systemic diseases with an expected survival of <12 months 5. Inability to obtain or completely archive baseline imaging/pathological/molecular data; 6. Investigator's judgment that the patient has severe cognitive or psychiatric disorders that prevent cooperation with scale assessments and follow-up; 7. Refusal or inability to provide biological specimens; 8. Participation in other interventional clinical trials (drug/device) that conflict with follow-up time points.

Design outcomes

Primary

MeasureTime frame
2-month overall survival rate;12-month progression-free survival rate;

Secondary

MeasureTime frame
Tumor recurrence;Postoperative complications;Neurological function;Quality of life;

Countries

China

Contacts

Public ContactZhengquan Yu

The First Affiliated Hospital of Soochow University

zhengquan.yu@neurosci.com.cn+86 187 6813 2032

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 3, 2026